Christopher Ogden net worth and biography

Christopher Ogden Biography and Net Worth

Mr. Ogden joined CytomX in August of 2021 after a 16-year tenure at Eli Lilly and Company where he held senior financial leadership positions including most recently as chief financial officer of Lilly Diabetes. Prior to his role in Lilly Diabetes, Mr. Ogden was the chief financial officer and treasurer of Lilly del Caribe in Puerto Rico. Over the course of his career at Eli Lilly, Mr. Ogden held financial leadership roles that included drug development, manufacturing, commercial operations, and investor relations. Mr. Ogden received his M.B.A. from Harvard Business School and his B.A. in economics from Wabash College.

What is Christopher Ogden's net worth?: The estimated net worth of Christopher Ogden is at least $1.09 million as of March 18th, 2025. Ogden owns 201,026 shares of CytomX Therapeutics stock worth more than $1,093,581 as of February 24th. This net worth evaluation does not reflect any other assets that Ogden may own. Learn More about Christopher Ogden's net worth.
How do I contact Christopher Ogden?: The corporate mailing address for Ogden and other CytomX Therapeutics executives is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. CytomX Therapeutics can also be reached via phone at (605) 515-3185 and via email at [email protected]. Learn More on Christopher Ogden's contact information.
Has Christopher Ogden been buying or selling shares of CytomX Therapeutics?: Christopher Ogden has not been actively trading shares of CytomX Therapeutics over the course of the past ninety days. Most recently, Christopher Ogden sold 8,551 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a transaction totalling $5,130.60. Following the completion of the sale, the chief financial officer now directly owns 201,026 shares of the company's stock, valued at $120,615.60. Learn More on Christopher Ogden's trading history.
Who are CytomX Therapeutics' active insiders?: CytomX Therapeutics' insider roster includes Marcia Belvin (SVP), Sean McCarthy (CEO), Christopher Ogden (CFO), and Lloyd Rowland (General Counsel). Learn More on CytomX Therapeutics' active insiders.
Are insiders buying or selling shares of CytomX Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 79,947 shares worth more than $47,968.20. The most recent insider tranaction occured on March, 18th when CEO Sean A Mccarthy sold 37,656 shares worth more than $22,593.60. Insiders at CytomX Therapeutics own 6.6% of the company. Learn More about insider trades at CytomX Therapeutics.
Information on this page was last updated on 3/18/2025.

Christopher Ogden Insider Trading History at CytomX Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2025	Sell	8,551	$0.60	$5,130.60	201,026
8/20/2024	Sell	1,984	$1.23	$2,440.32	108,077
3/19/2024	Sell	2,971	$2.09	$6,209.39	85,686
3/16/2023	Sell	516	$1.98	$1,021.68	37,772

Christopher Ogden Buying and Selling Activity at CytomX Therapeutics

CytomX Therapeutics Company Overview

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Today's Range

Now: $5.44

$5.44

$5.74

50 Day Range

MA: $4.97

$3.88

$6.09

2 Week Range

Now: $5.44

$0.40

$6.35

Volume

1,890,436 shs

Average Volume

3,280,351 shs

Market Capitalization

$921.73 million

P/E Ratio

13.60

Dividend Yield

N/A

Beta

2.44